Market revenue in 2023 | USD 451.2 million |
Market revenue in 2030 | USD 1,259.9 million |
Growth rate | 15.8% (CAGR from 2023 to 2030) |
Largest segment | Reagents |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Reagents, Kits, Instruments, Enzymes, Services |
Key market players worldwide | Roche Holding AG, Thermo Fisher Scientific Inc, Eisai Co Ltd, Novartis AG ADR, Element Biosciences, Dovetail Genomics, Illumina Inc, Promega, Abcam PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to epigenetics market will help companies and investors design strategic landscapes.
Reagents was the largest segment with a revenue share of 33.11% in 2023. Horizon Databook has segmented the Canada epigenetics market based on reagents, kits, instruments, enzymes, services covering the revenue growth of each sub-segment from 2018 to 2030.
Canada has several research institutions and universities engaged in research in genomics, molecular biology, & biotechnology. The demand for epigenetics in research applications is likely to be driven by exploration of gene-editing technologies by these institutions. According to an article by the Pan Canadian Genomic Library, the government of Canada would invest USD 15 million over 5 years.
Facilitating the capture, storage, and secure access of Canadian data. This database meets the demand for equitable & sustainable information management and contributes to the growth & advancement of epigenetics research and applications in the country. Epigenetics is crucial in dealing with the complexities of cancer.
According to an article by the Canadian Cancer Society, in 2023, researchers projected that Canada would witness 239,100 newly diagnosed cancer cases, accompanied by 86,700 cancer-related fatalities. Remarkably, these figures exclude instances of non-melanoma skin cancer.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada epigenetics market , including forecasts for subscribers. This country databook contains high-level insights into Canada epigenetics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account